Navigation Links
Lengthening time a drug remains bound to a target may lead to improving diagnostics, therapy
Date:4/25/2010

ANAHEIM, CA Studies led by Stony Brook University professor of chemistry Peter J. Tonge indicate that modifications that enhance the time a drug remains bound to its target, or residence time, may lead to better diagnostic and therapeutic agents.

Tonge will present these results at the American Society for Biochemistry and Molecular Biology's annual meeting in a talk titled "Slow Onset Inhibitors of Bacterial Fatty Acid Biosynthesis: Residence Time, In Vivo Activity and In Vivo Imaging." The talk will be held in Anaheim Convention Center Room 304C, on Sunday April 25 at 9:55 am PST.

"Our research team believes that many drugs are effective because they have long residence times on their target," says Tonge, Director of Infectious Disease Research at the Institute for Chemical Biology & Drug Discovery. "This concept has largely been ignored by investigators, and residence time is not usually incorporated into the drug discovery process."

Tonge explains that most drug discovery efforts obtain only data on the thermodynamic affinity of the drug for its target, measurements that are made at constant drug concentration. However, the Stony Brook University-led research factors in residence time, which he emphasizes is critical for activity in vivo where drug concentrations fluctuate with time.

"The central component of our work is that the length of time a drug remains bound to a target is very important for the activity of the compound in vivo," he adds.

Tonge, together with collaborators at Colorado State University and the University of Wrzburg in Germany, have developed a series of compounds that inhibit an enzyme target from Francisella tularensis, where the in vivo antibacterial activity of the compounds correlates with their residence time on the target and not with their thermodynamic affinity for the target. This resulted in a direct correlation between residence time and in vivo activity against an infectious agent.

The research team has also developed a long residence time inhibitor of an enzyme drug target in Mycobacterium tuberculosis and demonstrated that this compound has antibacterial activity in an animal model of tuberculosis.

Because compounds with long residence times should accumulate in bacteria, Tonge explains that the research may lead to the development of agents to image bacterial populations in vivo using positron emission tomography. He says that researchers could then further the concept and develop a method for non-invasive imaging of bacterial populations in humans for both diagnostic purposes and also to monitor bacterial load during drug therapy, thereby helping to chart a drug's effectiveness against bacterial infection.


'/>"/>

Contact: Nicole Kresge
nkresge@asbmb.org
202-316-5447
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Northern forests do not benefit from lengthening growing season
2. Ancient remains put teeth into Barker hypothesis
3. A year after discovery, Congos mother lode of gorillas remains vulnerable
4. Lead-based consumer paint remains a global public health threat
5. Analysis of Copernicus putative remains support identity
6. Laughter remains good medicine
7. Laughter remains good medicine
8. Accelerated bone turnover remains after weight loss
9. New technique determines the number of fat cells remains constant in all body types
10. Chesapeake Bay ecosystem health remains poor, but slightly improved in 2007
11. Fear of being laughed at crosses cultural boundaries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   ... data sensor technology, and STMicroelectronics (NYSE: ... spectrum of electronics applications, announced today the launch ... kit for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 /PRNewswire/ ... the formation of its Medical/Clinical Advisory Board.  This ... veterans who enhance the range and depth of ... of its novel prenatal diagnostic tests.  These experts ... strategic guidance for the company,s product development and ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... and development (R&D), today announced the launch of Data Science Services ... the rapidly evolving field of precision medicine. , Data Science Services ...
(Date:1/19/2017)... 19, 2017  ArmaGen, Inc., today announced that ... as chief executive officer, as well as a ... to ArmaGen more than 17 years of executive ... of biotherapeutics and pharmaceuticals. "Mathias ... experience and skillset necessary to lead ArmaGen to ...
(Date:1/19/2017)... Linda, Ca (PRWEB) , ... January 18, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, was ... American News. The awards program is based entirely on merit and decided upon ...
Breaking Biology Technology: